Cipla

{
  "main_header": {
    "sid": 597145,
    "name": "Cipla",
    "stock_name": "Cipla",
    "full_name": "Cipla Ltd.",
    "name_url": "stocks-analysis/cipla",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,467.70",
    "chg": 3.9,
    "chgp": "0.27%",
    "dir": 1,
    "prev_price": "1,463.80",
    "mcapval": "118,927.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 500087,
    "symbol": "CIPLA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE059A01026",
    "curr_date": "Aug 10, 03:30 PM",
    "curr_time": "03:52 AM",
    "last_traded_at": "Aug 10, 03:30 PM IST",
    "bse_nse_vol": "9.38 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 10, 2026",
    "traded_date_str": "2026 08 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cipla-597145-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cipla Ltd. Valuation Shifts Signal Price Attractiveness Challenges Amid Sector Comparisons",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-valuation-shifts-signal-price-attractiveness-challenges-amid-sector-comparisons-4144524",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/CiplaLtd_valuationdot_4144524.png",
        "date": "2026-08-10 08:01:02",
        "description": "Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating. This change reflects evolving market perceptions and invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical averages and peer benchmarks."
      },
      {
        "title": "Cipla Ltd. Ends Week Flat at Rs.1,472: Mixed Technicals and Elevated Valuation Shape Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-ends-week-flat-at-rs1472-mixed-technicals-and-elevated-valuation-shape-outlook-4143558",
        "imagepath": "",
        "date": "2026-08-08 16:19:39",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Aug 3:</strong> Stock opens at Rs.1,469.00, down 0.27% amid Sensex gains</p>\n                    <p><strong>Aug 4:</strong> Technical momentum shifts to mildly bullish; valuation moves from fair to expensive</p>\n                    <p><strong>Aug 6:</strong> Stock rebounds with a 1.72% gain to Rs.1,475.00</p>\n                    <p><strong>Aug 7:</strong> Week closes slightly lower at Rs.1,472.00 (-0.20%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,472.95</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div..."
      },
      {
        "title": "P/E at 33.29 vs Industry's 36.68: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-and-institutional-dynamics-in-2026-4141260",
        "imagepath": "",
        "date": "2026-08-07 09:21:23",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> currently trades at a P/E of 33.29, which is approximately 9.2% below the Pharmaceuticals & Biotechnology industry average of 36.68. This discount suggests that the market is valuing the company slightly more conservatively than its sector peers, despite Cipla’s status as a large-cap stock with a market capitalisation of ₹1,18,890.60 crores. The valuation gap may reflect concerns over growth prospects or competitive pressures, but it also implies a potential margin of safety relative to the sector’s average valuation. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"ctx\">Previously..."
      },
      {
        "title": "P/E at 32.73 vs Industry's 36.91: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-and-institutional-dynamics-in-2026-4139452",
        "imagepath": "",
        "date": "2026-08-06 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p>The current P/E of 32.73 for <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> represents a discount of approximately 11.3% relative to the sector average of 36.91. This valuation gap suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives risks not fully reflected in the broader industry. Given the company’s large-cap status with a market capitalisation of ₹1,18,672.48 crores, such a discount is significant and invites a closer look at performance metrics and technical indicators to understand the underlying dynamics. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla..."
      },
      {
        "title": "Cipla Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cipla-ltd-is-rated-hold-by-marketsmojo-4137756",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/CiplaLtd_mojoScore_4137756.png",
        "date": "2026-08-05 10:10:55",
        "description": "Cipla Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 July 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "P/E at 32.73 vs Industry's 36.85: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-mixed-market-performance-4137399",
        "imagepath": "",
        "date": "2026-08-05 09:20:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p>The current P/E of 32.73 for <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> contrasts with the sector average of 36.85, indicating the stock trades at a meaningful discount to its industry peers. This valuation differential suggests that investors may be pricing in either a more cautious outlook on Cipla’s near-term earnings growth or reflecting sector-wide headwinds that have not impacted Cipla as severely. The discount is particularly notable given Cipla’s status as a large-cap pharmaceutical company with a market capitalisation of ₹1,17,509.18 crores. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>’s P/E..."
      },
      {
        "title": "Cipla Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4134727",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/CiplaLtd_technicaldot_4134727.png",
        "date": "2026-08-04 08:05:37",
        "description": "Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a slight dip in price, the stock’s technical profile suggests a cautiously optimistic outlook, with recent upgrades in its Mojo Grade signalling improved investor sentiment."
      },
      {
        "title": "Cipla Ltd. Valuation Shifts Signal Price Attractiveness Change Amid Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-valuation-shifts-signal-price-attractiveness-change-amid-sector-dynamics-4134350",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/CiplaLtd_valuationdot_4134350.png",
        "date": "2026-08-04 08:00:54",
        "description": "Cipla Ltd., a stalwart in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably in recent months, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a recalibration of price attractiveness amid evolving market dynamics and peer comparisons."
      },
      {
        "title": "P/E at 33.25 vs Industry's 37.19: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-and-institutional-dynamics-amid-sectoral-shifts-4133110",
        "imagepath": "",
        "date": "2026-08-03 09:20:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 33.25, which is approximately 10.6% below the Pharmaceuticals & Biotechnology sector average of 37.19. This discount suggests that the market is pricing in either a more cautious outlook on Cipla's earnings growth or perceives relative risks compared to its peers. The sector's elevated P/E reflects optimism about growth prospects and innovation pipelines, yet Cipla's valuation indicates a more tempered investor sentiment. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>'s sizeable market capitalisation of ₹1,18,413.97 crores conf..."
      }
    ],
    "total": 1157,
    "sid": "597145",
    "stock_news_url": "https://www.marketsmojo.com/news/cipla-597145"
  },
  "announcements": [
    {
      "details": "Cipla Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "09-Dec-2019"
    },
    {
      "details": "Cipla Limited has informed the Exchange that its wholly owned subsidiary Cipla (EU) Limited, holding 60% stake in Cipla Pharma Lanka (Private) Limited {Cipla Pharma Lanka), Sri Lanka, has signed an agreement with CitiHealth Imports",
      "source": "NSE",
      "caption": "Cipla Limited - Acquisition",
      "datetime": "28-Nov-2019"
    },
    {
      "details": "Cipla Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "21-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has declared <strong>650%</strong> dividend, ex-date: 05 Jun 26",
          "dt": "2026-06-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has announced <strong>3:2</strong> bonus issue, ex-date: 24 Apr 06",
          "dt": "2006-04-24",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cipla Ltd. Valuation Shifts Signal Price Attractiveness Challenges Amid Sector Comparisons

2026-08-10 08:01:02

Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a fair to an expensive rating. This change reflects evolving market perceptions and invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical averages and peer benchmarks.

Read full news article

Cipla Ltd. Ends Week Flat at Rs.1,472: Mixed Technicals and Elevated Valuation Shape Outlook

2026-08-08 16:19:39

Key Events This Week

Aug 3: Stock opens at Rs.1,469.00, down 0.27% amid Sensex gains

Aug 4: Technical momentum shifts to mildly bullish; valuation moves from fair to expensive

Aug 6: Stock rebounds with a 1.72% gain to Rs.1,475.00

Aug 7: Week closes slightly lower at Rs.1,472.00 (-0.20%)

Week Open

Rs.1,472.95

Week CloseRead full news article

P/E at 33.29 vs Industry's 36.68: What the Data Shows for Cipla Ltd.

2026-08-07 09:21:23

Valuation Picture: Discount to Industry P/E

Cipla Ltd. currently trades at a P/E of 33.29, which is approximately 9.2% below the Pharmaceuticals & Biotechnology industry average of 36.68. This discount suggests that the market is valuing the company slightly more conservatively than its sector peers, despite Cipla’s status as a large-cap stock with a market capitalisation of ₹1,18,890.60 crores. The valuation gap may reflect concerns over growth prospects or competitive pressures, but it also implies a potential margin of safety relative to the sector’s average valuation. Previously...

Read full news article

P/E at 32.73 vs Industry's 36.91: What the Data Shows for Cipla Ltd.

2026-08-06 09:20:50

Valuation Picture: Discount to Industry P/E

The current P/E of 32.73 for Cipla Ltd. represents a discount of approximately 11.3% relative to the sector average of 36.91. This valuation gap suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives risks not fully reflected in the broader industry. Given the company’s large-cap status with a market capitalisation of ₹1,18,672.48 crores, such a discount is significant and invites a closer look at performance metrics and technical indicators to understand the underlying dynamics. Cipla...

Read full news article

Cipla Ltd. is Rated Hold by MarketsMOJO

2026-08-05 10:10:55

Cipla Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 July 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

P/E at 32.73 vs Industry's 36.85: What the Data Shows for Cipla Ltd.

2026-08-05 09:20:37

Valuation Picture: Discount to Industry P/E

The current P/E of 32.73 for Cipla Ltd. contrasts with the sector average of 36.85, indicating the stock trades at a meaningful discount to its industry peers. This valuation differential suggests that investors may be pricing in either a more cautious outlook on Cipla’s near-term earnings growth or reflecting sector-wide headwinds that have not impacted Cipla as severely. The discount is particularly notable given Cipla’s status as a large-cap pharmaceutical company with a market capitalisation of ₹1,17,509.18 crores. Cipla Ltd.’s P/E...

Read full news article

Cipla Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals

2026-08-04 08:05:37

Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a slight dip in price, the stock’s technical profile suggests a cautiously optimistic outlook, with recent upgrades in its Mojo Grade signalling improved investor sentiment.

Read full news article

Cipla Ltd. Valuation Shifts Signal Price Attractiveness Change Amid Sector Dynamics

2026-08-04 08:00:54

Cipla Ltd., a stalwart in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably in recent months, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a recalibration of price attractiveness amid evolving market dynamics and peer comparisons.

Read full news article

P/E at 33.25 vs Industry's 37.19: What the Data Shows for Cipla Ltd.

2026-08-03 09:20:41

Valuation Picture: Discount Amid Sector Premiums

Cipla Ltd. trades at a P/E multiple of 33.25, which is approximately 10.6% below the Pharmaceuticals & Biotechnology sector average of 37.19. This discount suggests that the market is pricing in either a more cautious outlook on Cipla's earnings growth or perceives relative risks compared to its peers. The sector's elevated P/E reflects optimism about growth prospects and innovation pipelines, yet Cipla's valuation indicates a more tempered investor sentiment. Cipla Ltd.'s sizeable market capitalisation of ₹1,18,413.97 crores conf...

Read full news article

View All News